Donald Trump

Summary

Affiliation: Roswell Park Cancer Institute
Country: USA

Publications

  1. pmc Variants in the vitamin D pathway, serum levels of vitamin D, and estrogen receptor negative breast cancer among African-American women: a case-control study
    Song Yao
    Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Breast Cancer Res 14:R58. 2012
  2. pmc A dramatic, objective antiandrogen withdrawal response: case report and review of the literature
    Yiu Keung Lau
    Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, USA
    J Hematol Oncol 1:21. 2008
  3. pmc Vitamin D deficiency and insufficiency among patients with prostate cancer
    Donald L Trump
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA
    BJU Int 104:909-14. 2009
  4. ncbi request reprint Chemotherapy of prostate cancer: present and future
    Donald Trump
    Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Curr Urol Rep 4:229-32. 2003
  5. pmc Vitamin D: considerations in the continued development as an agent for cancer prevention and therapy
    Donald L Trump
    Department of Medicine, The Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Cancer J 16:1-9. 2010
  6. ncbi request reprint Anti-tumor activity of calcitriol: pre-clinical and clinical studies
    Donald L Trump
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    J Steroid Biochem Mol Biol 89:519-26. 2004
  7. doi request reprint Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer
    Donald L Trump
    Roswell Park Cancer Institute, Buffalo, NY, USA
    Prostate 71:1264-75. 2011
  8. ncbi request reprint Phase II trial of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancer
    Donald L Trump
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Cancer 106:2136-42. 2006
  9. ncbi request reprint Vitamin D compounds: clinical development as cancer therapy and prevention agents
    Donald L Trump
    Departments of Medicine and Pharmacology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Anticancer Res 26:2551-6. 2006
  10. pmc CYP24A1 inhibition enhances the antitumor activity of calcitriol
    Josephia R Muindi
    Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, New York 14263, USA
    Endocrinology 151:4301-12. 2010

Research Grants

Detail Information

Publications83

  1. pmc Variants in the vitamin D pathway, serum levels of vitamin D, and estrogen receptor negative breast cancer among African-American women: a case-control study
    Song Yao
    Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Breast Cancer Res 14:R58. 2012
    ..We hypothesized that racial differences in 25OHD levels, as well as in inherited genetic variations, may contribute, in part, to the differences in tumor characteristics...
  2. pmc A dramatic, objective antiandrogen withdrawal response: case report and review of the literature
    Yiu Keung Lau
    Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, USA
    J Hematol Oncol 1:21. 2008
    ..We report a case in which a dramatic decline of serum PSA levels associated with a dramatic improvement in radiologic disease was achieved with bicalutamide discontinuation...
  3. pmc Vitamin D deficiency and insufficiency among patients with prostate cancer
    Donald L Trump
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA
    BJU Int 104:909-14. 2009
    ..To assess the frequency of vitamin D deficiency among men with prostate cancer, as considerable epidemiological, in vitro, in vivo and clinical data support an association between vitamin D deficiency and prostate cancer outcome...
  4. ncbi request reprint Chemotherapy of prostate cancer: present and future
    Donald Trump
    Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Curr Urol Rep 4:229-32. 2003
    ..Randomized trials of taxane versus mitoxantrone-based therapies are underway. New agents and applications of current agents in adjuvant settings should be explored if survival in men with prostate cancer is to be improved...
  5. pmc Vitamin D: considerations in the continued development as an agent for cancer prevention and therapy
    Donald L Trump
    Department of Medicine, The Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Cancer J 16:1-9. 2010
    ....
  6. ncbi request reprint Anti-tumor activity of calcitriol: pre-clinical and clinical studies
    Donald L Trump
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    J Steroid Biochem Mol Biol 89:519-26. 2004
    ..These results demonstrate that high intermittent doses of calcitriol can be administered to patients without toxicity, that the MTD is yet to be determined and that calcitriol has potential as an anti-cancer agent...
  7. doi request reprint Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer
    Donald L Trump
    Roswell Park Cancer Institute, Buffalo, NY, USA
    Prostate 71:1264-75. 2011
    ..This two-part study assessed the safety and tolerability of combined treatment with zibotentan (ZD4054), a specific endothelin A receptor antagonist, plus docetaxel in patients with metastatic castration-resistant prostate cancer...
  8. ncbi request reprint Phase II trial of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancer
    Donald L Trump
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Cancer 106:2136-42. 2006
    ..The combination of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) plus dexamethasone was studied based on evidence that dexamethasone potentiates the antitumor effects of calcitriol and ameliorates hypercalcemia...
  9. ncbi request reprint Vitamin D compounds: clinical development as cancer therapy and prevention agents
    Donald L Trump
    Departments of Medicine and Pharmacology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Anticancer Res 26:2551-6. 2006
    ....
  10. pmc CYP24A1 inhibition enhances the antitumor activity of calcitriol
    Josephia R Muindi
    Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, New York 14263, USA
    Endocrinology 151:4301-12. 2010
    ....
  11. ncbi request reprint Vitamin D signalling pathways in cancer: potential for anticancer therapeutics
    Kristin K Deeb
    Department of Pharmacology, Roswell Park Cancer Institute, Buffalo, New York, USA
    Nat Rev Cancer 7:684-700. 2007
    ..Here, we outline the epidemiological, preclinical and clinical studies that support the development of 1alpha,25(OH)2D3 and vitamin D analogues as preventative and therapeutic anticancer agents...
  12. doi request reprint Effect of 25-hydroxyvitamin D status on serological response to influenza vaccine in prostate cancer patients
    Manpreet K Chadha
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York, USA
    Prostate 71:368-72. 2011
    ..We conducted a prospective influenza vaccination study to determine the influence of vitamin D status on serological response to influenza vaccine in prostate cancer (CaP) patients...
  13. ncbi request reprint Phase I and pharmacokinetic study of weekly docetaxel, cisplatin, and daily capecitabine in patients with advanced solid tumors
    Marwan G Fakih
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Clin Cancer Res 11:5942-9. 2005
    ..Docetaxel, cisplatin, and capecitabine are three active chemotherapeutic agents with different mechanisms of action. This phase I study investigated the feasibility and pharmacokinetics of this combination given on a weekly schedule...
  14. pmc 1,25D3 enhances antitumor activity of gemcitabine and cisplatin in human bladder cancer models
    Yingyu Ma
    Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York, USA
    Cancer 116:3294-303. 2010
    ..The authors investigated whether 1,25D3 could enhance the antitumor activity of gemcitabine and cisplatin in bladder cancer model systems...
  15. doi request reprint Phase 2 trial of weekly intravenous 1,25 dihydroxy cholecalciferol (calcitriol) in combination with dexamethasone for castration-resistant prostate cancer
    Manpreet K Chadha
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Cancer 116:2132-9. 2010
    ....
  16. ncbi request reprint Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer
    George Wilding
    Department of Medicine, University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin 53792, USA
    Cancer 106:1917-24. 2006
    ..In this pilot Phase I trial, the authors evaluated the tolerability, efficacy, and pharmacokinetics of gefitinib combined with estramustine and docetaxel in patients with HRPC...
  17. ncbi request reprint Calcitriol (1,25-dihydroxycholecalciferol) selectively inhibits proliferation of freshly isolated tumor-derived endothelial cells and induces apoptosis
    Geraldine Flynn
    Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, N Y, USA
    Oncology 70:447-57. 2006
    ..Thus calcitriol exerts differential effects on TDEC compared to normal cells...
  18. ncbi request reprint Antitumor effects of two less-calcemic vitamin D analogs (Paricalcitol and QW-1624F2-2) in squamous cell carcinoma cells
    Adebusola A Alagbala
    Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, N Y, USA
    Oncology 70:483-92. 2006
    ..These less-calcemic vitamin D analogs are as effective as calcitriol in vitro and are promising for prevention and treatment of cancer and other diseases...
  19. pmc A phase I and pharmacokinetics study of intravenous calcitriol in combination with oral dexamethasone and gefitinib in patients with advanced solid tumors
    Josephia R Muindi
    Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Cancer Chemother Pharmacol 65:33-40. 2009
    ..v.) calcitriol administered in combination with a fixed oral dose of dexamethasone and gefitinib in patients with refractory solid tumors...
  20. ncbi request reprint Differential antiproliferative effects of calcitriol on tumor-derived and matrigel-derived endothelial cells
    Ivy Chung
    Department of Molecular Pharmacology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Cancer Res 66:8565-73. 2006
    ..These results show that TDEC were more sensitive than MDEC to the antiproliferative effects of calcitriol despite apparently normal VDR content and structure of signaling axis in both cell types...
  21. pmc Epigenetic regulation of vitamin D 24-hydroxylase/CYP24A1 in human prostate cancer
    Wei Luo
    Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Cancer Res 70:5953-62. 2010
    ..Our findings indicate that repression of CYP24A1 gene expression in human prostate cancer cells is mediated in part by promoter DNA methylation and repressive histone modifications...
  22. ncbi request reprint Pharmacokinetics of liquid calcitriol formulation in advanced solid tumor patients: comparison with caplet formulation
    Josephia R Muindi
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA
    Cancer Chemother Pharmacol 56:492-6. 2005
    ..83). We conclude that the commercially available liquid 1,25-D(3) formulation offers no PK advantage over caplet formulation...
  23. pmc Calcitriol enhances gemcitabine anti-tumor activity in vitro and in vivo by promoting apoptosis in a human pancreatic carcinoma model system
    Wei Dong Yu
    Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, NY, USA
    Cell Cycle 9:3022-9. 2010
    ..Our study suggests that calcitriol and gemcitabine in combination promotes caspase-dependent apoptosis, which may contribute to increased anti-tumor activity compared to either agent alone...
  24. ncbi request reprint Vitamin D-related therapies in prostate cancer
    Candace S Johnson
    Cancer Metastasis Rev 21:147-58. 2002
    ..Studies continue to define the MTD of calcitriol whichcan be safely administered on this intermittent schedule either alone or with other agents and to evaluate the mechanisms of calcitriol effects in prostate cancer...
  25. ncbi request reprint Anti-proliferative effects of calcitriol on endothelial cells derived from two different microenvironments
    Ivy Chung
    Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    J Steroid Biochem Mol Biol 103:768-70. 2007
    ....
  26. ncbi request reprint CYP24 splicing variants are associated with different patterns of constitutive and calcitriol-inducible CYP24 activity in human prostate cancer cell lines
    Josephia R Muindi
    Department of Medicine, Roswell Park Cancer Institute, Elm and Carlson Streets, Buffalo, NY 14263, USA
    J Steroid Biochem Mol Biol 103:334-7. 2007
    ..These results demonstrate that calcitriol treatment modulates CYP24 splicing, and suggests that differences in CYP24 splicing are associated with different patterns of CYP24 activity...
  27. pmc Pretreatment serum concentrations of 25-hydroxyvitamin D and breast cancer prognostic characteristics: a case-control and a case-series study
    Song Yao
    Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, New York, United States of America
    PLoS ONE 6:e17251. 2011
    ..Results from epidemiologic studies on the relationship between vitamin D and breast cancer risk are inconclusive. It is possible that vitamin D may be effective in reducing risk only of specific subtypes due to disease heterogeneity...
  28. ncbi request reprint A phase I pharmacokinetic and pharmacodynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumors
    Marwan G Fakih
    Department of Medicine, Roswell Park Cancer Institute and The University at Buffalo, NY 14263, USA
    Clin Cancer Res 13:1216-23. 2007
    ..Therefore, we conducted a phase I study of calcitriol and gefitinib to determine the maximum tolerated dose (MTD) of this combination...
  29. ncbi request reprint Monocyte fructose 1,6-bisphosphatase and cytidine deaminase enzyme activities: potential pharmacodynamic measures of calcitriol effects in cancer patients
    Josephia R Muindi
    Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Cancer Chemother Pharmacol 59:97-104. 2007
    ....
  30. pmc Characterization of Vitamin D insensitive prostate cancer cells
    Adebusola A Alagbala
    Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    J Steroid Biochem Mol Biol 103:712-6. 2007
    ..In summary, VDI cells are less responsive to the antiproliferative effects of calcitriol. Understanding Vitamin D insensitivity will further clinical development of Vitamin D compounds for prevention and treatment of CaP...
  31. ncbi request reprint Epigenetic silencing of CYP24 in tumor-derived endothelial cells contributes to selective growth inhibition by calcitriol
    Ivy Chung
    Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    J Biol Chem 282:8704-14. 2007
    ....
  32. ncbi request reprint The antitumor efficacy of calcitriol: preclinical studies
    Candace S Johnson
    Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Anticancer Res 26:2543-9. 2006
    ..These studies demonstrated that calcitriol has significant antiproliferative activity in a number of pre-clinical model systems and form the groundwork for on-going clinical studies investigating calcitriol as an anticancer agent...
  33. pmc Epigenetic silencing of CYP24 in the tumor microenvironment
    Candace S Johnson
    Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    J Steroid Biochem Mol Biol 121:338-42. 2010
    ..These data suggest that epigenetic silencing of CYP24 modulates cellular responses to calcitriol...
  34. ncbi request reprint Pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 in normal mice after systemic exposure to effective and safe antitumor doses
    Josephia R Muindi
    Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA
    Oncology 66:62-6. 2004
    ..The objective of this study was to determine plasma calcitriol PK in normal mice at doses of calcitriol which are active in suppressing tumor growth...
  35. pmc 1alpha,25-Dihydroxyvitamin D3 potentiates cisplatin antitumor activity by p73 induction in a squamous cell carcinoma model
    Yingyu Ma
    Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Mol Cancer Ther 7:3047-55. 2008
    ..The combination treatment may provide a more effective therapeutic regimen in cancer treatment...
  36. pmc Chemotherapy is linked to severe vitamin D deficiency in patients with colorectal cancer
    Marwan G Fakih
    Department of Medicine, Roswell Park Cancer Institute and The University at Buffalo, Buffalo, NY 14263, USA
    Int J Colorectal Dis 24:219-24. 2009
    ..We performed a retrospective study to assess the impact of metastatic disease and chemotherapy treatment on vitamin D status in patients with colorectal cancer residing in Western New York...
  37. pmc Role of vitamin D receptor in the antiproliferative effects of calcitriol in tumor-derived endothelial cells and tumor angiogenesis in vivo
    Ivy Chung
    Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Cancer Res 69:967-75. 2009
    ..These results indicate that calcitriol-mediated antiproliferative effects on TDEC are VDR-dependent and loss of VDR can lead to abnormal tumor angiogenesis...
  38. ncbi request reprint Calcitriol (1,25-dihydroxycholecalciferol) potentiates activity of mitoxantrone/dexamethasone in an androgen independent prostate cancer model
    Sharmila Ahmed
    Department of Medicine, University of Pittsburgh School of Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, USA
    J Urol 168:756-61. 2002
    ..Therefore, we investigated the effect of calcitriol on the antitumor efficacy of mitoxantrone and dexamethasone or mitoxantrone/dexamethasone in the PC-3 androgen independent prostate cancer model...
  39. ncbi request reprint A limited sampling method for the estimation of serum calcitriol area under the curve in cancer patients
    Josephia R Muindi
    Center for Clinical Pharmacology, Department of Medicine, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    J Clin Pharmacol 43:894-900. 2003
    ..90, p = 0.0001). These results show that serum calcitriol AUC0-12 h after s.c. and p.o. calcitriol administration is accurately estimated using pretreatment and 2- and 6-hour blood samples...
  40. doi request reprint The role of vitamin D in cancer prevention and treatment
    Aruna V Krishnan
    Department of Medicine, Division of Endocrinology, Stanford University School of Medicine, Stanford, CA 94305 5103, USA
    Endocrinol Metab Clin North Am 39:401-18, table of contents. 2010
    ..The reasons for the lack of impressive beneficial effects in clinical trials compared with the substantial efficacy seen in preclinical models are discussed...
  41. ncbi request reprint Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer
    Tomasz M Beer
    Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health and Science University, Mail Code CR 145, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA
    Cancer Chemother Pharmacol 59:581-7. 2007
    ..DN-101 is a new, high-dose, oral formulation of calcitriol under investigation for the treatment of cancer. We sought to evaluate the tolerability and pharmacokinetics (PK) of weekly doses of DN-101 in patients with advanced cancer...
  42. pmc Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy
    Guru Sonpavde
    Department of Medicine, Section of Medical Oncology, Baylor College of Medicine, Houston, Texas, USA
    Cancer 115:4104-9. 2009
    ....
  43. pmc Phenotype-specific CpG island methylation events in a murine model of prostate cancer
    Marta Camoriano
    Department of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Cancer Res 68:4173-82. 2008
    ..In conclusion, phenotype-specific hypermethylation events were associated with the overexpression of different genes and may provide new markers of prostate tumorigenesis...
  44. ncbi request reprint Role of nongenomic activation of phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase 1/2 pathways in 1,25D3-mediated apoptosis in squamous cell carcinoma
    Yingyu Ma
    Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, NY 14201, USA
    Cancer Res 66:8131-8. 2006
    ..1,25D3 induces the activation of phosphatidylinositol 3-kinase/Akt, which suppresses 1,25D3-mediated apoptosis and prolongs the survival of SCC cells...
  45. ncbi request reprint Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial
    Stuart Hinton
    Department of Medicine, Indiana University Medical Center and The Walther Cancer Institute, Indianapolis, Indiana, USA
    Cancer 97:1869-75. 2003
    ....
  46. ncbi request reprint Interleukin-6 polymorphism is associated with more aggressive prostate cancer
    Dongfeng Tan
    Department of Pathology, Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    J Urol 174:753-6. 2005
    ..We determined the association of IL-6 polymorphism with prostate cancer progression...
  47. ncbi request reprint Phase I and pharmacokinetic study of vinblastine and high-dose megestrol acetate
    Khalid Matin
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Cancer Chemother Pharmacol 50:179-85. 2002
    ..Based on these data, we performed a phase I study of high-dose oral megestrol acetate and vinblastine to evaluate the safety of this regimen...
  48. ncbi request reprint Interleukin-6 protects LNCaP cells from apoptosis induced by androgen deprivation through the Stat3 pathway
    Soo Ok Lee
    Department of Medicine and Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Prostate 60:178-86. 2004
    ..Previous studies demonstrated that IL-6 promotes androgen-independent growth of prostate cancer cells. In this study, the effect of IL-6 on apoptosis induced by androgen deprivation was investigated...
  49. ncbi request reprint Altered VDR-mediated transcriptional activity in prostate cancer stroma
    Alejandro A Hidalgo
    Department of Urologic Oncology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    J Steroid Biochem Mol Biol 103:731-6. 2007
    ..These results indicate that VDR structure/function and coregulator recruitment to 1alpha,25(OH)(2)D(3) regulated genes is altered in the CaP stroma microenvironment...
  50. ncbi request reprint Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA)
    Soo Ok Lee
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Prostate 66:1070-5. 2006
    ..In this study, we tested whether selenium (methylselenocysteine (MSC)) affects tumor growth of human prostate cancer cells by targeting AR signaling in vivo...
  51. doi request reprint Phase II study of fulvestrant (Faslodex) in castration resistant prostate cancer
    Manpreet K Chadha
    Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, New York 14263, USA
    Prostate 68:1461-6. 2008
    ..In this trial we investigated the tolerability and efficacy of fulvestrant, a pure estrogen receptor antagonist, in the treatment of castration resistant prostate cancer (CRPC)...
  52. ncbi request reprint Does bone mineral density and knowledge influence health-related behaviors of elderly men at risk for osteoporosis?
    Avni Patel
    Osteoporosis Prevention and Treatment Center, Division of Endocrinology and Metabolism, Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA
    J Clin Densitom 6:323-30. 2003
    ..However, they were not more likely to make significant health-related lifestyle changes after obtaining the results of their bone mass...
  53. ncbi request reprint RNA interference targeting Stat3 inhibits growth and induces apoptosis of human prostate cancer cells
    Soo Ok Lee
    Department of Medicine and Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York, USA
    Prostate 60:303-9. 2004
    ..These results demonstrate that targeting Stat3 signaling using siRNA technique may serve as a novel therapeutic strategy for treatment of prostate cancer expressing constitutively activated Stat3...
  54. ncbi request reprint Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers
    Ramesh K Ramanathan
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Cancer Chemother Pharmacol 57:465-74. 2006
    ..The pharmacokinetics of MGd were also evaluated...
  55. ncbi request reprint The case for early androgen deprivation: the data should not be ignored
    Sharmila Ahmed
    Department of Medicine, Division of Hematology and Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA 14213, USA
    Urol Oncol 7:77-80. 2002
  56. pmc Stat3 activation of NF-{kappa}B p100 processing involves CBP/p300-mediated acetylation
    Nagalakshmi Nadiminty
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Proc Natl Acad Sci U S A 103:7264-9. 2006
    ..Furthermore, overexpression of p52 protected cells from apoptotic cell death. Thus, activation of the processing of p100 to p52 by Stat3 may represent one of the common pathways used by cancer cells to survive and escape therapy...
  57. ncbi request reprint Decreased tumor blood flow as measured by positron emission tomography in cancer patients treated with interleukin-1 and carboplatin on a phase I trial
    Theodore F Logan
    University of Pittsburgh, Pennsylvania 15260, USA
    Cancer Chemother Pharmacol 50:433-44. 2002
    ....
  58. ncbi request reprint Proteasome-mediated degradation of cell division cycle 25C and cyclin-dependent kinase 1 in phenethyl isothiocyanate-induced G2-M-phase cell cycle arrest in PC-3 human prostate cancer cells
    Dong Xiao
    Department of Pharmacology and University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA
    Mol Cancer Ther 3:567-75. 2004
    ..Furthermore, the results of the present study point toward involvement of both caspase-8- and caspase-9-mediated pathways in apoptosis induction by PEITC...
  59. ncbi request reprint Antiproliferative effects of 1alpha,25-dihydroxyvitamin D(3) and vitamin D analogs on tumor-derived endothelial cells
    Ronald J Bernardi
    Department of Pharmacology, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pennsylvania 15213, USA
    Endocrinology 143:2508-14. 2002
    ..Thus, our work supports the hypothesis that angiogenesis inhibition plays a role in the antitumor effects of 1,25-(OH)(2)D(3)...
  60. ncbi request reprint Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer
    H Barton Grossman
    M D Anderson Cancer Center, Houston, USA
    N Engl J Med 349:859-66. 2003
    ..We evaluated the ability of neoadjuvant chemotherapy to improve the outcome in patients with locally advanced bladder cancer who were treated with radical cystectomy...
  61. ncbi request reprint Allyl isothiocyanate, a constituent of cruciferous vegetables, inhibits growth of PC-3 human prostate cancer xenografts in vivo
    Sanjay K Srivastava
    Department of Pharmacology, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA
    Carcinogenesis 24:1665-70. 2003
    ..In conclusion, the results of the present study indicate that AITC administration inhibits growth of PC-3 xenografts in vivo by inducing apoptosis and reducing mitotic activity...
  62. ncbi request reprint Cisplatin potentiates 1,25-dihydroxyvitamin D3-induced apoptosis in association with increased mitogen-activated protein kinase kinase kinase 1 (MEKK-1) expression
    Pamela A Hershberger
    Department of Pharmacology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA
    Mol Cancer Ther 1:821-9. 2002
    ..We propose that the increased cytotoxicity for 1,25D3/cisplatin results from cisplatin enhancement of 1,25D3-induced apoptotic signaling through MEKK-1...
  63. ncbi request reprint Phase III study of combined chemohormonal therapy in metastatic prostate cancer (ECOG 3882): an Eastern Cooperative Oncology Group study
    Andrea N Leaf
    Department of Hematology Oncology 111D, Veterans Affairs Medical Center, 800 Poly Place, Brooklyn, NY 11209, USA
    Med Oncol 20:137-46. 2003
    ..Failure-free survival duration did reach statistical significance in the combined-therapy group (p = 0.012), although the actual durations were short (2.6-3.2 mo). There was no difference in overall survival between the two groups...
  64. ncbi request reprint Vitamin D receptor: a potential target for intervention
    Candace S Johnson
    Department of Pharmacology, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA
    Urology 60:123-30; discussion 130-1. 2002
    ..Studies continue to define the MTD of calcitriol on this intermittent schedule, either alone or with other agents, and to evaluate the mechanisms of calcitriol effects in prostate cancer models...
  65. ncbi request reprint Glucocorticoids and treatment of prostate cancer: a preclinical and clinical review
    Marwan Fakih
    Department ofMedicine, Division of Hematology Oncology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    Urology 60:553-61. 2002
  66. ncbi request reprint Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel
    Josephia R Muindi
    Center for Clinical Pharmacology and Cancer Institute, University of Pittsburgh, PA 15213, USA
    Clin Pharmacol Ther 72:648-59. 2002
    ..An additional goal was to evaluate the relationship between calcitriol dose and hypercalcemia...
  67. ncbi request reprint Diallyl trisulfide-induced apoptosis in human prostate cancer cells involves c-Jun N-terminal kinase and extracellular-signal regulated kinase-mediated phosphorylation of Bcl-2
    Dong Xiao
    Department of Pharmacology and Medicine, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Oncogene 23:5594-606. 2004
    ..In conclusion, our data point towards important roles for Bcl-2, JNK and ERK in DATS-induced apoptosis in human prostate cancer cells...
  68. pmc Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy
    Susan L Greenspan
    Divisions of Geriatric Medicine and Endocrinology and Metabolism, University of Pittsburgh, Pittsburgh, PA 15213 3221, USA
    J Clin Oncol 26:4426-34. 2008
    ..Our objective was to examine changes in bone density and turnover with sustained, discontinued, or delayed oral bisphosphonate therapy in men receiving ADT...
  69. ncbi request reprint Bladder cancer. Clinical guidelines in oncology
    James E Montie
    J Natl Compr Canc Netw 4:984-1014. 2006
  70. ncbi request reprint Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial
    Maha H A Hussain
    University of Michigan, Ann Arbor, USA
    J Clin Oncol 25:2218-24. 2007
    ....
  71. ncbi request reprint Sulforaphane-induced cell death in human prostate cancer cells is initiated by reactive oxygen species
    Shivendra V Singh
    Department of Pharmacology and University of Pittsburgh Cancer Institute, Pennsylvania 15213, USA
    J Biol Chem 280:19911-24. 2005
    ....
  72. ncbi request reprint Population pharmacokinetic analysis of 17-(allylamino)-17-demethoxygeldanamycin (17AAG) in adult patients with advanced malignancies
    Xueyu Chen
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, Room 5 221A, 610 University Ave, Toronto, ON, Canada, M5G 2M9
    Cancer Chemother Pharmacol 55:237-43. 2005
    ....
  73. ncbi request reprint Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumors
    Laura L Jung
    Molecular Therapeutics and Drug Discovery Program, University of Pittsburgh Cancer Institute, PA 15213, Pittsburgh, USA
    Cancer Chemother Pharmacol 54:487-96. 2004
    ..Therefore, we evaluated the plasma pharmacokinetics and urine recovery of 9NC administered on three different schedules as part of phase I and phase II studies...
  74. ncbi request reprint Phase I and pharmacologic study of intermittently administered 9-nitrocamptothecin in patients with advanced solid tumors
    William C Zamboni
    Program of Molecular Therapeutics and Drug Discovery, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    Clin Cancer Res 10:5058-64. 2004
    ..In an effort to increase the dose administered per day and determine whether the daily dose or number of days of treatment influence toxicity, we performed a Phase I study of 9NC using intermittent schedules of administration...
  75. ncbi request reprint Pharmacokinetics and tolerability of a single dose of DN-101, a new formulation of calcitriol, in patients with cancer
    Tomasz M Beer
    Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, 97239, USA
    Clin Cancer Res 11:7794-9. 2005
    ..In this dose escalation study, we sought to evaluate the tolerability and pharmacokinetics of a single oral dose of DN-101, a high-dose calcitriol formulation...
  76. ncbi request reprint High prevalence of screening-detected prostate cancer among Afro-Caribbeans: the Tobago Prostate Cancer Survey
    Clareann H Bunker
    Department of Epidemiology, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, USA
    Cancer Epidemiol Biomarkers Prev 11:726-9. 2002
    ..These data support the hypothesis that populations of African descent share genetic and/or lifestyle factors that contribute to their elevated risk for prostate cancer...
  77. ncbi request reprint Peroxisome proliferator-activated receptor-gamma polymorphism, body mass and prostate cancer risk: evidence for gene-environment interaction
    Joseph M Zmuda
    Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA 15261, USA
    Oncology 70:185-9. 2006
    ..Peroxisome proliferator-activated receptor (PPAR)-gamma has been implicated in prostate cancer. In the present case-control study, we tested if a common Pro12Ala polymorphism in PPAR-gamma is associated with the risk of prostate cancer...
  78. ncbi request reprint Randomized trial of influenza vaccine with granulocyte-macrophage colony-stimulating factor or placebo in cancer patients
    Ramesh K Ramanathan
    University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    J Clin Oncol 20:4313-8. 2002
    ..To determine whether granulocyte-macrophage colony-stimulating factor (GM-CSF) would improve response to influenza vaccination in cancer patients...
  79. ncbi request reprint Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer
    Susan L Greenspan
    Osteoporosis Prevention and Treatment Center, University of Pittsburgh, Kaufmann Medical Building, Suite 1110, 3471 Fifth Avenue, Pittsburgh, Pennsylvania 15213 3221, USA
    J Clin Endocrinol Metab 90:6410-7. 2005
    ..Although androgen deprivation therapy (ADT) for prostate cancer is associated with bone loss, little is known about when this bone loss occurs...
  80. ncbi request reprint Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial
    Susan L Greenspan
    University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    Ann Intern Med 146:416-24. 2007
    ..Androgen deprivation therapy (ADT) in men with prostate cancer is associated with bone loss and fractures...
  81. ncbi request reprint Allyl isothiocyanate, a constituent of cruciferous vegetables, inhibits proliferation of human prostate cancer cells by causing G2/M arrest and inducing apoptosis
    Dong Xiao
    Department of Pharmacology, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, PA 15213, USA
    Carcinogenesis 24:891-7. 2003
    ..In conclusion, it seems reasonable to hypothesize that AITC, and possibly other ITCs, may find use in the treatment of human prostate cancers...
  82. ncbi request reprint Elevated seroprevalence of human herpesvirus 8 among men with prostate cancer
    Linda J Hoffman
    Department of Infectious Diseases and Microbiology, School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    J Infect Dis 189:15-20. 2004
    ..253; 95% CI, 0.77-3.54).Conclusions. HHV-8 seropositivity is elevated among men with prostate cancer compared with control subjects, which suggests that HHV-8 plays a role in the development of prostate cancer...
  83. ncbi request reprint Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers
    Ramesh K Ramanathan
    Molecular Therapeutics Drug Discovery Program, Biostatistics Department, Graduate School of Public Health, and Biostatistics Facility, University of Pittsburgh Cancer Institute, PA 15232, USA
    Clin Cancer Res 11:3385-91. 2005
    ..We did a phase I study of 17AAG to establish the dose-limiting toxicity and maximum tolerated dose and to characterize 17AAG pharmacokinetics and pharmacodynamics...

Research Grants11

  1. Vitamin D in Prostate Cancer: Tumor Vasculature Effects
    Donald Trump; Fiscal Year: 2006
    ....
  2. Evaluation of CYP24 as a Target for Enhancing Vitamin D*
    Donald Trump; Fiscal Year: 2006
    ..D receptor expression, expression of apoptosis markers whether a relationship exists between modulation of these effects in vitro on tumor cells and a significant antitumor response in vivo in prostate, pancreatic and lung cancer models ..
  3. Enhancing the Safety of Research Participants
    Donald Trump; Fiscal Year: 2003
    ..abstract_text> ..
  4. Implementation of Data Safety Monitoring Plan (DSMP)
    Donald Trump; Fiscal Year: 2002
    ..abstract_text> ..